5-[(4-Fluorophenyl)methoxy]-2-methyl-3,4-dihydroisoquinolin-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-[(4-Fluorophenyl)methoxy]-2-methyl-3,4-dihydroisoquinolin-1-one
• 化学式: C₁₇H₁₆FNO₂
• 分子量: 285.318
• InChiKey: GVODUQZTIWRMTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X4 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2021211839A1

  公开（公告）日：2021-10-21

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided. The Mas-Related G-protein (MRGPR) X4 modulators, are in particular isoindolinones and isoquinolinones substituted on the carbocyclic ring. The compounds are useful to treat itch associated conditions, pain associated conditions, or an autoimmune disorder.

  提供了一种调节MRGPR X4的方法，或者更具体地用于治疗依赖于MRGPR X4的疾病，方法是通过接触MRGPR X4或向需要的受试者施用具有Formula (I)结构的化合物的有效量，或其药学上可接受的异构体、消旋体、水合物、溶剂化合物、同位素或盐，其中m、n、p、t、A、B、Z、R1、R2和R3的定义如本文所述。还提供了含有这种化合物的药物组合物，以及这些化合物本身。具体来说，Mas-Related G-protein (MRGPR) X4调节剂是在碳环上取代的异吲哚酮和异喹啉酮。这些化合物可用于治疗与瘙痒相关的疾病、与疼痛相关的疾病或自身免疫性疾病。
• MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS
  申请人：Escient Pharmaceuticals, Inc.

  公开号：US20210340106A1

  公开（公告）日：2021-11-04

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.